Status:
UNKNOWN
A Research in Pharmacogenomics and Accurate Medication of Risperidone
Lead Sponsor:
Cui Yimin
Conditions:
Schizophrenia
Mental Illness
Eligibility:
All Genders
Brief Summary
Risperidone is a selective monoamine receptor antagonist. It plays an antipsychotic effect by antagonizing 5-HT2 / D2 receptor. As a second-generation antipsychotic drug, risperidone is metabolized to...
Detailed Description
Subjects with schizophrenia will be recuited from several sub-centers. The relevant gene polymorphisms and risperidone drug metabolism, drug adverse reaction parameters are monitored through drawing b...
Eligibility Criteria
Inclusion
- patients that meet with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychiatric Interview (MINI);
- patients who have never received risperidone treatment or who need re-administration of risperidone after previous treatment with risperidone;
- Subjects and / or their guardians who agree to sign the informed consent.
Exclusion
- patients who use CYP2D6 or CYP3A4 inducers or inhibitors as treatment drugs;
- patients with hepatic insufficiency;
- patients with renal insufficiency;
- patients who use other drugs that interact with risperidone;
- certain patients that the researchers consider to be unsuitable for the clinical trail.
Key Trial Info
Start Date :
October 22 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT03302364
Start Date
October 22 2017
End Date
June 1 2020
Last Update
August 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034